ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Fibroblast activation protein-targeted molecular imaging in interstitial lung disease: a systematic review.Annals of nuclear medicine · 2026Pooled it
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Article
- Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review.The British journal of radiology · 2026Review
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Exploratory evaluation of earlyEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Unravelling mesenteric fibrosis in small intestinal neuroendocrine tumours and implications for clinical management.Endocrine-related cancer · 2026Review
- Parametric mapping of dynamicCancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Fibroblast activation protein inhibitor (FAPI) PET imaging in pulmonary fibrosis: pathophysiology, clinical utility, and emerging theranostic applications.Respiratory research · 2026Review
- Molecular imaging of fibroblast activation in systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Article
- Comparative Evaluation of [68Ga]Ga-DOTA.SA.FAPi and [18F]FDG PET/CT in Metastatic Breast and Lung Cancer: Semiquantitative, Volumetric and Prognostic Assessment.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Digital Biopsy and Network Analysis of Dynamic [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Multidimensional lung imaging: integrated preclinical platforms enabling the identification of translational biomarkers for pulmonary research.Respiratory research · 2026Review
- Targeted depletion of activated fibroblasts via [Frontiers in immunology · 2026Article
- Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor prognosis, whereas some other ILDs, such as sarcoidosis, have a much better prognosis. A high proportion manifests as fibrotic ILD (fILD). Lung cancer (LC) is a frequent complication of fILD. Activated fibroblasts are crucial for fibrotic processes in fILD. The aim of this exploratory study was to evaluate the imaging properties of static and dynamic fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT in various types of fILD and to confirm FAP expression in fILD lesions by FAP immunohistochemistry of human fILD biopsy samples and of lung sections of genetically engineered (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.